Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma

Abstract

Activating mutations within the EGFR TK domain can be used to predict the risk of recurrence in curatively resected pulmonary adenocarcinoma.

Epidermal growth factor receptor inhibits colitis-associated cancer in mice

“…decreased tumor recurrence following resection (77). These observations are consistent with the findings that EGF inhibits murine colonic epithelial cell proliferation in vivo (7) and that EGF is an ineffective trophic agent for the colonic mucosa under unchallenged conditions (our unpublished observations).…”

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

“…Moreover, incidence of BM did not differ into molecular selected patients (EGFR mutant, KRAS mutant, ALK rearrangement) compared with wild-type patients [20,21]. There are some reports describing the predictive value of EGFR mutational status for the development of BM metastases in NSCLC [22,23]. Furthermore, EGFR amplification has also been suggested to be predictive of earlier BM development [24].…”

Factors associated with recurrence in patients with curatively resected stage I–II lung cancer

“…For example, we could not address the impact of the usage of inhaled corticosteroid (ICS) treatment for chronic obstructive pulmonary disease (COPD) [30,31] or the status of epidermal growth factor receptor (EGFR) mutation [32,33] on the risk of recurrence, because of the small size of our sample.…”